EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova® lid and lash hygiene product for the domestic eye care market, announces that Chairman, President and CEO Mark M. Sieczkarek will present at the LD Micro Main Event on Wednesday, December 7 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time). The conference is being held at the Luxe Sunset Hotel in Los Angeles.
Mr. Sieczkarek will be available for one-on-one meetings with the investment community on Wednesday, December 7. Please contact LD Micro at www.ldmicro.com/contact if you would like to arrange a meeting.
A live webcast and a replay of the LD Micro Main Event presentation will be available on the Company's website at http://novabay.com/investors/events/.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
Avenova, formulated with Neutrox®, is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s commercial name for its proprietary pure hypochlorous acid. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmeriSource Bergen.
Stay informed on NovaBay's progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website